Tumor heterogeneity describes differences between tumors. Tumor heterogeneity can refer to differences between (1) tumors in different patients, (2) cancer cells in an individual patient's tumor, or (3) a primary and metastatic tumor. Understanding the heterogeneity of a tumor can facilitate diagnosis and treatment.
DATE: April 9, 2019TIME: 9:00 AM PDTWe will provide a general introduction to the Single-Cell Western Technology (SCW) and then present data from 2 ongoing projects from the Col...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
DATE: November 28, 2018TIME: 7:00AM PSTSingle-cell genomics enables a deep dive into the mechanisms responsible for health and disease, in areas from cancer biology to neurob...
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...
Tumors are often categorized into standard molecular subtypes. However, largescale studies have demonstrated that patient heterogeneity in the regulatory make-up of tumors remain. At the tran...
DATE: March 22, 2018TIME: 09:00am PST, 12:00pm ESTGlioblastoma (GBM) is the most aggressive primary brain cancer, with nearly universal recurrence after treatment. GBMs are highly heter...
DATE: March 6, 2018TIME: 08:00am PST, 11:00am EST, 5:00pm CETRNA sequencing and expression arrays are transcriptomics techniques used to quantify transcribed genes and their isoforms. T...
The field of melanoma has been transformed by the parallel development of effective immune and targeted therapies. There is now strong evidence of cross-talk between oncogenic signaling...
Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors...
Cancer research diagnostic services in pathology laboratories worldwide have been negatively impacted by a lack of fresh-frozen tissue samples, the degradation of DNA and RNA in archival tiss...
The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by ma...
Recent advances in flow and mass cytometry have greatly expanded the number of immune cell parameters that can be interrogated, resulting in an improved understanding of the immune system het...
The realization of the promise of personalized molecular medicine requires efficient development and implementation of novel targeted therapeutics linked to molecular markers able to identify...
DATE: April 26, 2017TIME: 9:00AM PT, 12:00PM ETBiopsies from non-small cell lung cancer (NSCLC) and colorectal adenocarcinoma generally produce small, heterogeneous samples with li...
DATE: April 20th, 2017TIME: 10:00AM SGT, 11:00AM KST, 12:00PM AEST, 2:00PM NZSTWith increasing breadth and depth of genomics studies across a range of cancers, it is now apparent that t...
Despite vast investment for decades in cancer research and development, cancer is still among the leading causes of death worldwide and its toll is expected to rise by about 70% over the next...
DATE: January 27, 2017TIME: 4:00am PT, 7:00am ET, 1:00pm CETThe study of the tumor ecosystem and its cell-to-cell communications is essential to enable an understanding of tumor biology...
DATE: November 16, 2016
TIME: 8:00am PT, 11:00am ET
Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among wo...
Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented mas...
DATE: November 1, 2016
TIME: 8:00AM PT, 11:00AM ET
Metastatic cancer is an evolving, heterogeneous disease that becomes more complex over time through the selection of sub-clonal tumor po...
DATE: October 11, 2016
TIME: 7:00am PT, 10:00am ET
Monoclonal antibodies (mAbs) have emerged as important therapeutics for the treatment of life-threatening diseases. The succ...
Intra-tumor heterogeneity is a major obstacle to cancer treatment. Existing single-cell studies of intra-tumor heterogeneity have largely focused on DNA mutations; functional heterogeneity is...
DATE: April 9, 2019TIME: 9:00 AM PDTWe will provide a general introduction to the Single-Cell Western Technology (SCW) and then present data from 2 ongoing projects from the Col...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
DATE: November 28, 2018TIME: 7:00AM PSTSingle-cell genomics enables a deep dive into the mechanisms responsible for health and disease, in areas from cancer biology to neurob...
Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lun...
Tumors are often categorized into standard molecular subtypes. However, largescale studies have demonstrated that patient heterogeneity in the regulatory make-up of tumors remain. At the tran...
DATE: March 22, 2018TIME: 09:00am PST, 12:00pm ESTGlioblastoma (GBM) is the most aggressive primary brain cancer, with nearly universal recurrence after treatment. GBMs are highly heter...
DATE: March 6, 2018TIME: 08:00am PST, 11:00am EST, 5:00pm CETRNA sequencing and expression arrays are transcriptomics techniques used to quantify transcribed genes and their isoforms. T...
The field of melanoma has been transformed by the parallel development of effective immune and targeted therapies. There is now strong evidence of cross-talk between oncogenic signaling...
Currently, prostate cancer is the second leading cause of death from cancer in North America, the most frequent malignancy in men from all ethnicities, surpassing lung cancer. Prostate tumors...
Cancer research diagnostic services in pathology laboratories worldwide have been negatively impacted by a lack of fresh-frozen tissue samples, the degradation of DNA and RNA in archival tiss...
The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by ma...
Recent advances in flow and mass cytometry have greatly expanded the number of immune cell parameters that can be interrogated, resulting in an improved understanding of the immune system het...
The realization of the promise of personalized molecular medicine requires efficient development and implementation of novel targeted therapeutics linked to molecular markers able to identify...
DATE: April 26, 2017TIME: 9:00AM PT, 12:00PM ETBiopsies from non-small cell lung cancer (NSCLC) and colorectal adenocarcinoma generally produce small, heterogeneous samples with li...
DATE: April 20th, 2017TIME: 10:00AM SGT, 11:00AM KST, 12:00PM AEST, 2:00PM NZSTWith increasing breadth and depth of genomics studies across a range of cancers, it is now apparent that t...
Despite vast investment for decades in cancer research and development, cancer is still among the leading causes of death worldwide and its toll is expected to rise by about 70% over the next...
DATE: January 27, 2017TIME: 4:00am PT, 7:00am ET, 1:00pm CETThe study of the tumor ecosystem and its cell-to-cell communications is essential to enable an understanding of tumor biology...
DATE: November 16, 2016
TIME: 8:00am PT, 11:00am ET
Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among wo...
Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented mas...
DATE: November 1, 2016
TIME: 8:00AM PT, 11:00AM ET
Metastatic cancer is an evolving, heterogeneous disease that becomes more complex over time through the selection of sub-clonal tumor po...
DATE: October 11, 2016
TIME: 7:00am PT, 10:00am ET
Monoclonal antibodies (mAbs) have emerged as important therapeutics for the treatment of life-threatening diseases. The succ...
Intra-tumor heterogeneity is a major obstacle to cancer treatment. Existing single-cell studies of intra-tumor heterogeneity have largely focused on DNA mutations; functional heterogeneity is...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
